Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Inspire Medical Systems (INSP)

Inspire Medical Systems Q4 revenue up 25% to $239.7 million; 2025 EPS guided $2.10-$2.20

Positive Impact 3 of 5 earnings Written later

Inspire Medical Systems reported fourth-quarter 2024 revenue of $239.7 million, up 25% from a year earlier, and diluted earnings per share of $1.15 versus $0.49. It also reaffirmed 2025 revenue guidance of $940 million to $955 million and introduced 2025 diluted EPS guidance of $2.10 to $2.20, which gives shareholders a profit target for the year.

Key points

  • Q4 2024 net income was $35.2 million, with diluted EPS of $1.15 versus $0.49 a year earlier
  • Full-year 2024 revenue was $802.8 million, up 28%, with net income of $53.5 million and diluted EPS of $1.75
  • 2025 revenue guidance of $940 million to $955 million was reaffirmed; diluted EPS guidance of $2.10 to $2.20 was introduced
  • Q4 2024 gross margin was 85.0%, compared with 85.4% a year earlier

The filing

CompanyInspire Medical Systems (INSP)
Form8-K, current report
Filed with the SECFeb 10, 2025, 4:05 PM ET
Accession number0001609550-25-000009

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.